The USA has approximately 1466 biotechnology companies, including over 300 public firms (Ernst and Young, 2000; . The majority of firms are located within nine metropolitan regions (Boston^Cambridge, Los Angeles, San Diego, San Francisco, Philadelphia, New York, Seattle, Raleigh^Durham^Chapel Hill, and Washington, DCB altimore), which account for three quarters of the United States' largest biotechnology firms (Cortright and Mayer, 2002, page 3) . Research is the common element in the origins of the firms in the biotechnology clustersöuniversities and research centres are sources of scientific knowledge (Feldman and O'Malley, 1982) . Feldman (1985) noted that residential quality of life and the potential for expansion were important considerations as well at the initial stages of development of biotechnology firms in Silicon Valley, which is occasionally fondly referred to as the Siliclone Valley by industry insiders (Bagchi-Sen, 2004) . On the east coast, the presence of biotechnology firms in the Boston^Cambridge area can be directly attributed to the proactive role of Massachusetts Institute of Technology in fostering entrepreneurship in new technologies. In downstate New York, New Jersey, Maryland, and Pennsylvania (including Washington, DC, and Philadelphia), substantial concentrations of biotechnology activity are a function of the historical presence of the nation's largest pharmaceutical manufacturers and their R&D activity (Feldman and Schreuder, 1996) . The emergence of San Diego (Walcott, 2001; , Seattle (Haugh, 1995) , and Raleigh^Durham^Chapel Hill as biotechnology clusters is built upon wellfunded medical research establishments. Deeds et al (1999) find that one of the key relationships between these research centres and firms is prior research experience in the academic community.
The evolution of a concentration of activity and the nature of the research link are, however, complex. Feldman and Ronzio (2001) found evidence of regional specialisation and diversity, with only a limited degree of causality between research-centre specialisation and the composition of the local biotechnology industry. For example, Iowa shows specialisations in several agriculturally oriented fields and Massachusetts exhibits regional specialisation in therapeutics and transgenics, but California and New Jersey, both with a large number of firms, do not exhibit significant specialisations in any subfield. In the case of California, the diverse product focus mirrors the distribution of national firms across subfields. Hall and Bagchi-Sen (2001) , in a survey of firms in Canada, also found variations in links with universities across regions.
For example, biotechnology firms rank access to skilled scientists and basic research as the most important factor in Vancouver and Montreal but preferred the opportunity for coproduct-development efforts in assessing their location needs in Toronto. Hence, the complex university^industry^government relationship is a challenge for policymakers trying to understand how best to address the needs of firms in particular localities, as appears to be the case in San Diego (Walcott, 2001; .
In the USA, therefore, the growth of the biotechnology sector is attributed to the role of the university, the characteristics of the firm (entrepreneurship and managerial abilities), and the role of the government (Kenney, 1986) . Some of these necessary conditions are local attributes (for example, access to university research for a startup company) and others are not necessarily limited to the local area (for example, access to an industry partner). In a similar fashion, barriers to this sector encompass the lack of adequate and appropriate resources and collaborators, as well as regulatory stringency. Some of the initial conditions fostering the growth of this sector in the United States are: advancements in university research, federal policy allowing universities to take out patents, the entrepreneurial nature of some universities in fostering spin-offs, and the experience and willingness of venture capitalists involved in the information technology sector to invest in biotechnology-based ventures. Yet these factors alone are not enough to ensure a firm's success. Several studies have focused on the firm to understand which characteristics are important for survival and growth, with a specific focus on the organisational structure of firms (Argyres and Liebeskind, 2002; Greis et al, 1995) . These studies show that strong in-house R&D is a necessity. These firms also seek out appropriate collaborators for both upstream (research, design, and development) and downstream (manufacturing and commercialisation) activities [see Argyres and Liebeskind (2002) for a discussion of the relationship between Genentech and Roche].
In sum, the need for a policy environment conducive to the growth of this sector continues because firms at all stages require a supportive environment which will facilitate the availability of resources (skilled labour, funds, and space) and minimise the bottlenecks in the regulatory environment (regulations encompassing the protection of intellectual property rights, drug approval, and manufacturing processes). In the next sections we briefly discuss the main characteristics of federal policy and statelevel initiatives deemed to be important for this sector in the USA in mitigating some of these risks. Most of the literature on this sector is based on historical evidence (Prevezer, 1998) , case studies (Walcott, 2002) , or statistical analysis of macrolevel data (Deeds et al, 1999) ; only a few studies are based on large-scale firm-level surveys [for example, the Greis et al (1995) study of 244 US biotechnology firms]. This paper is an attempt to fill this gap by showing what firms regard as their needs and barriers, which firm-level strategies are seen as important for improving their business performance, and whether any government services or programmes are considered to be of importance in moving an innovation forward.
The role of the federal government
This is an industry in which government policy plays an important role in almost every stage of research, development, and commercialisation (see Feldman, 1985; Feldman and O'Malley, 1982; Prevezer, 1998) ö the experience from the past two decades shows that stable and supportive federal, as well as state and local, policy environments are necessary for the growth of this industry [see the Battelle Memorial Institute and State Science and Technology Industry study (BMI/SSTI, 2001) ]. Four main features of the federal system discussed here as affecting the entrepreneurial environment of the biotechnology industry are research funding, the ownership of intellectual property rights, policy regulating research collaborations, and rules governing the venture capital industry (Audretsch et al, 2002) .
Federal research funding has been crucial to the development of this industry. By the late 1970s, 11% of all US federally funded R&D was directed towards biomedical research (Senker, 1996, page 221) . In 2002 the NIH (National Institutes of Health) budget was US $23.6 billion and will be in the order of $27.3 billion in 2003 (NIH, 2003) . Research activity by itself, however, is not enough to ensure the growth of the biotechnology industry. For example, Atlanta and Houston are biomedical research centres with limited commercial activity. Therefore, state and local support appear to be critical not only for research but also for business development.
The protection of intellectual property rights through patenting is set by the US Congress and administered by the US Patent and Trademark Office. In 1980 the Bayh^Dole Act was passed to allow university researchers to take out patents. There are currently debates about the effect of this act on university-based patenting trends, the quality of university patents, and the impact of technology transfer from universities (Mowery et al, 2001; Rai and Eisenberg, 2003) . Researchers and private companies receive thousands of biotechnology-based patents in a given year (Dibner, 1999) öover 13 000 in 2000 (http://www.bio.org). Around 350 biotechnology-based medicines are in different stages of development and approximately 130 biotechnology-related drugs and vaccines have reached the market since the inception of the modern biotechnology sector in the United States, but only a few drugs account for nearly all the sales. Stringency in the drug-approval process has not always ensured the safety of a drug and in the past decade some drugs (not based on biotechnologies) have been recalled by the Food and Drug Administration (see the FDA website http://www.fda.gov). Therefore, the implementation of an efficient system to prove safety and efficacy is the current challenge facing the federal government (see ongoing discussions between the US Biotechnology Industry Organisation, and policymakers on http://www.bio.org). In addition to the FDA, the Environment Protection Agency and the US Department of Agriculture regulate this sector. The FDA not only decides which drugs will be approved for commercialisation but it also regulates the conditions for manufacturing pharmaceuticals and the direct advertisement of drugs to consumers (Walcott, 2002) . Later in this paper, the firm-level analysis will show that biotechnology firms find regulations to be barriers but, when interviewed, R&D personnel from small firms did not argue for a less stringent process but voiced their plea for help in understanding how to prepare patent applications and/or a proposal for the approval of a drug, vaccine, or new indication. For example, the Massachusetts Biotech Council organises regular seminars for local companies to understand ongoing developments in patent law and FDA approval processes.
The third area is public policy towards research collaboration, to foster entrepreneurship in high-technology sectors. The National Cooperative Research Act (NCRA), passed in 1984 (Audretsch et al, 2002; Hagedoorn et al, 2000) , created a registration process so that research joint ventures (RJVs) can disclose their research intentions to the Department of Justice. By 2002 there were 800 formal RJVs filed under NCRA. On average 15% of RJVs have at least one university partner and of these over 90% are US universities. Audretsch et al (2002, page 181) conclude that firms with university partnerships generally have greater productivity and greater patenting activity than those without, and that a key motive for the firm to undertake such collaboration is to gain access to university personnel (both graduate students and faculty) and laboratory facilities.
A fourth area is the indirect role the US government initially played in fostering the venture capital industry with supportive monetary and fiscal policies, allowing the stock market as an exit strategy for venture capital funded endeavours, supporting university-based research, and passing of the Small Business Investment Act (1958) [see Florida and Kenney (1988) and Dossani and Kenney (2002) for an extensive discussion of the US venture capital industry]. In 1973 government action indirectly harmed this industry through the passage of the Employment Retirement Income Security Act, which made``pension fund managers criminally liable for losses incurred in high-risk investments. This was interpreted to include venture capital funds ... pension managers shunned venture capital, nearly destroying the industry'' (Dossani and Kenney, 2002 , page 231).
The regional infrastructure for the biotechnology industry
The regional system in the USA mimics the national systemösome of the important components of state-level initiatives in California and Massachusetts, two states with a large concentration of biotechnology firms, are shown in table 1. State-level initiatives to foster the learning economy cover investments not only in hard infrastructure, such as transportation and communication systems, but also in softer, knowledge infrastructures, such as universities, research institutes, science parks, and technology-transfer centres (Cooke, 2002) . These are initiatives at the institutional level, the organisational level for firms, and the organisational level for governance.
Nearly every state in the USA now has some institutionalised support for the biotechnology industry, but this varies in the type and amount of resources allocated. In the early 1990s Massachusetts developed a strategic plan that is still being implemented. A survey of seventy-seven local and thirty-six state economic development agencies (Grudkova, 2001) reported that 83% listed biotechnology as one of their top two targets for industrial development. The downside of this level of interest is that such an emphasis on biotechnology has resulted in`bidding wars' between states attempting to entice firms to relocate by offering financial incentives (Feldman and Ronzio, 2001, page 11) .
Key elements of state involvement are discussed below to illustrate how the state supports the biotechnology sector. First, state initiatives in funding and the promotion of networking are discussed. Next, a brief summary of state-level regulations, such as tax breaks or R&D credits, right-to-know legislation, and drug-price control is presented. The final point addressed is the effort to improve the human capital base.
Funding
States have an important role in improving the supply of early-stage finance. Even in regions with strong venture capital markets, such as San Diego, the lack of pre-seed and seed capital is a problem (BMI/SSTI, 2001), because the process of developing new biotechnology products is time consuming and expensive (see Dibner, 1999; Lee and Burrill, 1996) and biotech is not as popular as other investments, accounting for about 5% in 2000 (PriceWaterhouseCoopers, 2001, quoted in Cortright and Mayer, 2002, page 21) . Of this share, most goes to a small number of locations. Only five of the top biotechnology metropolitan areasöthe leaders (Boston^Cambridge, and San Francisco) and three areas in which biotech is growing rapidly (San Diego, Seattle, and Raleigh^Durham^Chapel Hill)ömeet the condition of a patient venture capital market, accounting for 75% of the new venture capital in biopharmaceuticals in the past six years, 74% of the value of research contracts from pharmaceutical firms, and 56% of the new biotech businesses formed during the 1990s. To increase the volume of venture capital, over half of the states (28) now have one or more publicly supported seed or venture funds that can invest in bioscience-related companies. Five states have funds that exclusively invest in bioscience-related companies: California, Massachusetts, North Carolina, Ohio, and Wisconsin. 
Tax policy
Manufacturers' investment credit ösome manufacturers eligible for 6% credit, which can be claimed against tax; unused credit can be carried forward 8 years. R&D tax creditö15% for research done in-house. Net operating loss (NOL) carryoverö biotechnology and biopharma companies given preferential treatment on NOLs: 100% may be carried over for up to 8 years.
Credit against excise tax for leased personal propertyöR&D companies are eligible. Tax credit for a corporation renting or leasing tangible property ö3% of the value of qualifying property leased and placed in qualified use during the taxable year. R&D tax creditölike investment tax credit, R&D tax credit is available to offset excise tax liability.
The research funding gap is recognised by many states. Fifteen states have passed budgets and/or enabling legislation to use some portion of their tobacco settlements for bioscience-related R&D. There is a strong emphasis on tobacco-related research (except in Massachusetts) or research into tobacco-related illnesses. However, there is a lack of emphasis on funding commercialisation efforts. Only three states (Michigan, Ohio, and Pennsylvania) have explicitly targeted some of the funding for commercialisation.
In others, there has been increased state funding of academic bioscience research centres, for example, the Institute for Bioengineering, Biotechnology, and Quantitative Biomedical Research in California ($100 million in state funding), New York's Strategically Targeted Academic Research centres (each centre's funding is approximately $15 million), and Texas legislature's appropriation of $800 million for science, engineering, research, and commercialisation activities in 2001öapproximately half of which is for new laboratories and equipment in the state's universities and colleges (BMI/SSTI, 2001) .
Another funding trend is the increased state interest in addressing the space needs of bioscience firms (BMI/SSTI, 2001, page 13), most of which initially lease rather than own spaces such as wetlabs. Nine states have used traditional economic development programmes, including loan, loan guarantee, and other public financing programmes, to fund facilities for bioscience companies [Alabama, Alaska, Arkansas, Connecticut, Maryland (Feldman and Ronzio (2001) , Massachusetts, New Jersey, Pennsylvania, and Wisconsin]. In addition, several states have provisions for biotechnology incubators and research parks (for example, BioSquare in Boston). The nature of activities permitted in these areas (types and volume of manufacturing, or sorts of buildings or laboratories that can be erected) are controlled by local regulations.
Promoting networking and trade associations
There is a growth of biotechnology networking and trade associations across all states. The use of collaboration or strategic partnering, particularly networking, is one of the most widely recognised strategies for moving innovation forward in this sector (Greis et al, 1995; Hall and Bagchi-Sen, 2001; Woiceshyn and Hartel, 1996) . Thirty-five states have at least one networking organisation (BMI/SSTI, 2001, page 14); some states (including Massachusetts, New York, and Washington) have more than one.
Recent research has questioned the assumption that collaboration and networking are necessary for success in the biotechnology industry. Instead, the capacity of the firm to innovate is a factor which should not be neglected (Freel, 2003 , page 767; see also Mangematin et al, 2003 , on the same point). Yet Freel (page 767) is sceptical of these claims and argues on the basis of his study of nearly 600 small and medium-sized enterprises (SMEs) that this pattern is not universal,``It seems that external collaboration is, unequivocally, neither a necessary or sufficient condition for successful innovation.'' The path toward innovation is riddled with barriers for SMEs in high-technology sectors (Britton, 1989) : for example financial constraints; weak research, product development, or marketing skills; limited production capabilities or distribution channels; or a lack of experience in protecting intellectual property (Hall and Bagchi-Sen, 2001; Woiceshyn and Hartel, 1996) . Pisano et al (1988) had shown that strong in-house R&D is necessary for collaboration and Bagchi-Sen (2004) reconfirmed their finding by showing that more firms with higher levels of R&D intensity engage in R&D alliances, especially research collaborations with universities.
Even studies which have highlighted the importance of collaboration have suggested that the necessity of collaboration at the local level is overstated and that many alliances occur with scientists located outside the local area, including other countries.
Spatial proximity to scientists, a necessary condition in early stages of development (Keeble et al, 1998) , is not necessarily the most important factor determining the nature, extent, or intensity of collaborative linkages as the firm develops a portfolio of patents, scientific reputation, and cash flow and signals a promising future in moving an innovation forward in the near future. Hence, policymakers, in not only facilitating institutional linkages but also trying to promote supplier connection and distribution networks, may not be directing their efforts towards the most appropriate forms of intervention.
Regulations and human capital
State regulations are a critical factor at the state level. For example, the US tax structure, as in Germany and Canada, but unlike that in the United Kingdom, means that states have independent tax-raising and tax-setting powers. This has important implications for the industrial environmentöthe more imaginative the state, the better the environment. In biosciences, BMI/SSTI (2001) finds that a recent trend has been to restructure state tax policies [for example, R&D tax credit, investment tax credits, capital gains cuts, net operating loss (NOL) provisions, and tax credit transferability] to address better the growth of the industry. A number of states (such as California, Connecticut, New Jersey, and Texas) allow NOLs to be carried forward for varying numbers of years: in California for eight years but in Texas and Connecticut up to twenty years.
Similarly, wide variations exist in the legislative framework governing research and the market structure. BMI/SSTI (2001) argues that California has the most liberal and advanced regulatory but not necessarily supportive environment for the biopharmaceutical industry and is often used as a yardstick with which to compare other states. California enacted genetic privacy legislation;`right-to-know' legislation; legislation placing price controls on prescription drugs; and a Medicaid reimbursement policy, under which California has a restricted formulary with supplemental rebates, prior authorisation, and mandatory generic substitution for over 600 commonly prescribed drugs. Thus the potential profit for pharmaceutical companies is less in California than in other states which have not enacted this legislation. In contrast, Massachusetts has not enacted right-to-know legislation but has enacted medical record privacy legislation; it has not enacted prescription price control; and has an open Medicaid formulary. New York has enacted pricing and right-to-know legislation but not price controls nor a restricted formulary. Maryland has not enacted price controls on prescription drugs. Hence the profitability of the regional market for drugs varies by stateöwhich to some extent counterbalances the huge advantage of the investment in the science base.
States have also introduced measures to improve the stock of human capital, but this is an area of policy which is underdeveloped. BMI/SSTI (2001, page 18) interestingly observes that the biotechnology industry``has not experienced the same problems of insufficient labour as the information and communication technology industry.'' Hence human capital issues facing firms have been more often to do with finding experienced managers and regulatory personnel. The BMI/SSTI study reports that bioscience workforce initiatives have been introduced to address the skills supply. These include the establishment of two-year associate's degree programmes in Massachusetts and thirteen other states, and changes in curricula at colleges and universities to reflect better the workforce needs of bioscience firms. Examples of changes in higher education include a PhD programme in biotechnology offered by two universities in Maine, a new master's programme focused on biotechnology in New York, and outreach programmes to bioscience companies to determine skill training and education needs in Florida and New York.
To summarise, so far we have discussed the characteristics of the US biotechnology sector and presented some of the main features of the federal and state policy frameworks that form the environment in which firms operate. Unlike other studies which are based on historical evidence, case studies, or regional data, the next section presents a firm-level view of the importance of location characteristics, barriers, strategies, and government programmes and services for innovation and commercialisation. In particular, the study focuses on the relative importance of in-house factors (such as research skills) with respect to regional or locational factors (such as access to R&D funding and the presence of government programmes) in helping or hindering innovation and business performance in biotechnology firms.
3 Survey methodology, data, and findings A large-scale postal survey of biotechnology firms in the United States was administered in order to collect the data used in this study. An extensive postal survey was followed by intensive on-site interviews of R&D personnel (usually the vice-president of R&D) of 22 biotechnology firms across the United States. These interviews provide some further explanation of the survey results as noted in the discussion of the extensive postal survey. The US biotechnology industry sampling frame was developed by combining databases of the North American Biotechnology Directory (I.E.I., 1997) and the Biotechnology Industry Guide (Dibner, 1999) . From a total sample base of 1185 US companies, a random subsample of 597 firms (50%) was chosen to receive questionnaires. The seven-page postal questionnaire was first mailed to these biotechnology companies in April 1998. The survey included the following sections: firm characteristics, innovation performance, collaboration trends, barriers, firm-level strategies, and an assessment of location factors and government programmes. Follow-up telephone calls and faxes were made to approximately 300 companies through May 1998. During that period 99 surveys were either returned undeliverable, or responses were received stating that the companies were not biotechnology companies; 3 firms indicated that they were unable to participate because of company policy or legal status. In total, 50 usable responses were received, yielding a response rate of 10% from the usable sample of 498. Second requests were mailed in May 1998 to 187 companies which had not responded or which had not been contacted by telephone to date. Telephone calls and faxes continued through May, and 43 additional firms were removed from the sample because responses indicated that these firms did not consider themselves to be biotechnology companies. During this period an additional 24 usable responses were obtained, yielding a total response rate of (74a455) 16.3%. In June a third request was mailed to the firms yet to respond. Telephone calls and faxes continued through the end of June; 31 additional firms were removed from the sample as a result of this effort, and 52 additional usable responses were received, bringing the final response rate to 29.7% (126 firms responded from a final sample of 424 firms).
The geographic distribution of the sample and the corresponding distribution of the respondents is as follows: 28.1% of the total 424 firms and 20.7% of the 126 respondents came from California; 8% of the 424 and 10.3% of the 126 responses came from Massachusetts. Other states with at least 4% of respondents per state included Maryland, downstate New York, New Jersey, North Carolina, Pennsylvania, Texas, and Washington. Areas outside these states account for 28.8% of the sample and 28.7% of the respondents; these firms are distributed across 21 other states with Connecticut and upstate New York accounting for 5 and Wisconsin accounting for 4 firms. The geographical distribution of respondents (126 firms) closely matches the geographical distribution of the 597 firms surveyed by Hall and Bagchi-Sen (2001)öthere is no evidence of a nonresponse bias (the Mann^Whitney test comparing the geographical distribution of firms surveyed and the distribution of respondents, yielded a p-value of 0.127 for a two-tailed test). Table 2 presents the revenue-based measures reported by survey respondents. Approximately, two thirds of the firms have $10 million dollars or less in revenue. Revenue sources are primarily product sales and contracts, regardless of firm location. In a similar fashion, the geographic source of revenue includes different locations in the USA as well as sources outside the USA. This is further confirmed by the fact several firms (48% of the total) are regular exporters. The primary market segment of respondents is human health (diagnostic and therapeutic) and the average R&D intensity (the percentage of total revenue expended for R&D) is 42%. The average R&D intensity of biotechnology firms in California and Massachusetts is much higher than the national average as shown table 2. These firms also focus on the therapeutic end or on drug discovery.
First-specific characteristics

The importance of place
This section of the survey assesses how firms rate the importance of place-specific characteristics (the availability of university researchers, venture capital, and so on) for innovation and commercialisation of biotechnologies (table 3) . At first glance, one can see that, irrespective of regions, firms note the importance of proximity to the founder's residence (for example, the founder may be a university professor), proximity to university researchers (possibly the founder and his or her team), and the quality of life in the region. These conditions have been discussed by Feldman (1985) in an earlier study of the biotechnology industry in Silicon Valley. More recently, Florida (2002) examined the spatial association between talent and quality of life and further substantiated the importance of place-specific characteristics in fostering knowledge-based industries. Interviews indicated that start-ups need seed funding and other assistance with day-to-day operations from local development organisations. Very few firms in California or Massachusetts indicated any desire to relocate R&D facilities to locations with cheaper overhead costsöhowever, some have no choice but to establish manufacturing in places (elsewhere in the United States) with a favourable regulatory atmosphere toward manufacturing (for example, North Carolina). The continued importance of proximity to universities is indicative of the nature of business in the biotechnology industry where firms focus on early breakthroughs and discoveries in federally funded bioscience departments; also, a large percentage of these firms have their roots in university departments. The low importance rating for almost all variables is surprisingöa most striking finding is the low rating of the importance of government assistance. The relative importance of various government programmes and services is discussed later.
Another observation is the relatively low importance given to the availability of venture capital in the local area^this may suggest that the competition for funds extends beyond the local region. The national average and the mean value for California and Massachusetts show that the availability of specialist services and lower cost of land and energy are considered to be somewhat important. The above findings show that, when it comes to location, firms focus on operating costs pertaining to space and the provision of specialist services (legal, testing facilities, training programmes, and export marketing) and facilities. The BMI/SSTI study shows that states are aware of the need for facilities but not all states recognise the importance of specialist services or external inputs in moving an innovation forward through a complex and stringent regulatory process or through the formation of strategic alliances. Scale: 1 not important, 2 somewhat important, 3 important, 4 very important, 5 critically important.
Barriers
This section of the survey assesses barriers to innovation and commercialisation in the biotechnology industry (table 4) . Three levels of barrier are evaluated: financial, regulatory, and resource. The findings show that regulations and the lack of human capital (managers and researchers) are important. All firms interviewed, regardless of location, consider US government regulations a barrier to innovation because of the length of time and amount of data needed to succeed. For example, the cost involved for all levels of testing to prove safety and efficacy of a drug for the FDA is often the reason cited by biotechnology firms for seeking collaboration with pharmaceutical companies. The survey findings show that the firms also rate foreign regulations an important barrier because a large number of firms are involved in exporting biotechnology-based products in international markets and they need to protect their intellectual property rights in these countries as well as meeting country-specific regulations for commercialisation. Regulatory barriers for drugs and vaccines as opposed to life-science technologies are much tougher in European markets, which are the main destinations of US products (see Salter and Smith, 2002) . Throughout the 1990s and up to the present, the United States has been the main source of biotechnology products to Western Europe; now, Belgium, Ireland, and the Netherlands are becoming important sources of exports to the USA bringing the US trade balance in biotechnology products to an all-time low. For example, US exports increased from $661.2 million to $1594.2 million, but imports increased from $32.1 million to $1006.4 million (National Science Board, 2002). US companies are facing import competition. Policies promoting the provision of specialist services for export market development are needed to expand markets of US products in and beyond Western Europe.
Resource limitations, such as the dearth of skilled researchers and managers, are important barriers. It should be noted that in table 3 proximity to university researchers was noted as a locational needöfirm-level interviews showed that this need is not just for accessing new discoveries but also for potential researchers who are being trained in the doctoral programmes. Furthermore, some professors do collaborate with firms in conducting laboratory experiments. Biotechnology firms continue to face the challenge of reaching a happy balance between science and entrepreneurship such that business performance can be improved. All biotechnology firms, irrrespective of size, have, since the downturn in the US stock market in 2001, recognised the need for business development as an important strategic function, as noted during the in-person interviews. The recognition of this barrier (the lack of skilled managers and researchers) is also evident in the current policy initiatives undertaken in every state through the promotion of the study of life sciences, bioengineering, and biotechnology management in major state universities and the creation of technical training programmes in community colleges (http://www.bio.org/tax/battelle.pdf ).
The current provision of funds and facilities for R&D accompanied by initiatives to promote networking may not alleviate regulatory barriers or create a pool of skilled managers readily available for consultationö however, such help with the creation of softer, knowledge infrastructures will definitely allow firms to reallocate their limited human resources to business management, including the time and effort needed to prepare for the protection of intellectual property rights and FDA approval procedures.
What affects business performance?
This section of the survey examines the importance of a series of factors that may explain business performance (revenue generation) of the firms (table 5) . This evaluation assesses the relative importance to business performance of in-house conditions versus externalities. The national averages and the data from California and Massachusetts show that in-house capabilities geared toward product development are extremely important in determining the financial fate of a biotechnology company. These in-house strengths are: research capability, product quality, managerial skills, and the ability to recognise commercial applications of technology. Most firms interviewed recognise that personnel involved in product development cannot be trained in universities; the top personnel in the field usually gain their experience in a few biotechnology and pharmaceutical companies. These scientists and managers often move from one firm to another and, therefore, firms in this industry are faced with intense competition to hire the best talent. How policies can be geared to foster skills in product development is a challenge. Bio-incubators are being constructed to fill this gap in certain parts of the country. The success or failure of these incubators will be an important area of future research in the analysis of the biotechnology industry [some examples are Arkansas Bioventures, the AlphaCenter (partly owned by the Johns Hopkins University) in Maryland, MBIdeas Innovation Center in Massachusetts, and the City of Norfolk Biotechnology Incubator].
An assessment of government programmes
This section of the survey assesses the importance rating of selected government programmes and services by biotechnology firms ( (Greis et al, 1995) shows that partnering with pharmaceutical or chemical or other biotechnology companies is an important strategy to move an innovation forward. This is further corroborated by an analysis of alliances between traditional pharmaceutical companies and new biotechnology firms (Rothaermel, 2001) , which shows that the incumbent pharmaceuticals have achieved successful biotechnology-based product development as an outcome of their alliances. Recent state initiatives have focused on funding R&D, building incubators or science parks, encouraging intraindustry networks, and providing tax breaks and other related provisions to manage the cost of innovation and commercialisation. This leaves out the main difficulty faced by biotechnology firms (noted above) which are mostly small, that is, coordinating entrepreneurship (raising money), R&D (discovery), and business management (selling ideas or knowledge and products). The provision of assistance to help firms collaborate appears to be a way forward. In recent years, alliances in the biotechnology industry have been considered one of the most important strategic moves for risk reduction in R&D, the improvement of product quality, and the enhancement of reputation or credibility for investorsöall of which are necessary for commercial success (Bagchi-Sen, 2004 ). However, start-ups still have a long way to go before they are ready to collaborate. Furthermore, not all private or public companies have products in the market. These start-ups and other public and private firms need assistance in competing nationwide for venture capital funds, overcoming regulatory hurdles, locating suppliers, and identifying markets for their patented technology or products and services. Most of these firms are run by a few people who have to perform well as entrepreneurs, scientists, and managers at the same time öin other words, even today, the industry suffers from a gulf among three professional and organisational cultures: entrepreneurial, scientific, and managerial. If policy provisions can ease this burden, then a new chapter in the relationship between a knowledge-based industry and the state will be written. The survey-based study shows that US biotechnology firms continue to face barriers in accessing resources (skills and finance) and coping with regulations. All firms interviewed, irrespective of geographic location, face problems in getting the right scientist or the right manager. Small firms in biotechnology clusters have difficulties attracting skilled workers from outside because the cost of living in San Francisco and Cambridge is so high. Hence they are competing to hire from a limited pool of talent within these clusters. Elsewhere, the cost of living may be lower but it is difficult to recruit scientists and managers to these locations. In the case of skills, it does appear that there is some complacency in policy circles about the development of much-needed human capital to foster the growth of biotechnology-based firms. For example, the section in the BMI/SSTI report on human resource initiatives gave far fewer examples than for most other substantive modes of policy intervention. The current survey-based study shows that a necessary skill requirement is for specialist services which is not emphasised in the current policy framework. If necessary,`the promotion of networking' as a policy provision could be further developed to include service providers of importance to firms in different market segments or at different stages of development in the biotechnology industry.
As noted above, in addition to the mail-out survey, interviews with firm-level personnel show that problems in accessing finance and skills vary depending on the market segment and the stage of development. For example, therapeutics and diagnostic companies need to be examined separately in future studies. The drug discovery or therapeutic companies may not generate any revenue for a long time or their only source of revenue could be licensing fees. These firms need assistance with technology transfer, that is, finding clients for their knowledge products (for example, patents). Firms focused on diagnostic products may have products to market but resource limitations and the lack of networking opportunities may curtail their potential to generate revenues, which is much needed for further R&D, especially in an atmosphere of cutbacks in venture capital funding. Then, there are firms focusing on research, which are constantly trying to find investors to support R&D.
The challenge for policymakers is to develop local policy initiatives which will help them attract investors, including foreign ones. The competition for investors, including venture capital funds, is fierce. Financial assistance through tax reliefs, R&D credits, and the purchase of laboratory equipment or supplies are initiatives much needed by dedicated biotechnology firms. For example, the high rating of government programmes shows the need for R&D tax credits in this industry because this provision allows firms to save on operating costs. The current model of state funding for start-ups and incubators in designated biotechnology parks or science parks is attractive to policymakers because of the relative ease of delivery and attached positive image but is an easier policy target than some more sophisticated taxation and regulatory policies.
Our analysis shows that the regulatory challenges faced by biotechnology firms range from difficulties with local regulations to federal and international regulations. For example, local regulations control manufacturing facilities and variations in these can create bidding wars among states to attract biomanufacturing (as noted in Feldman and Ronzio, 2001 ). The interviews reveal that firms do not criticise federal regulations, but the time and cost involved in clinical trials deter dedicated biotechnology firms from integrating downstream activities into their company's operations. Rather, they opt for collaborations with pharmaceutical companies or are acquired by other pharmaceutical companies which are well equipped and experienced in handling patent as well as FDA applications (Rothaermel, 2001 ).
In line with Freel's (2003) arguments, the survey showed that collaborative strategies or the need to access local collaborators are not factors that receive high importance ratings. On the other hand, government programmes for fostering interindustry cooperation and technology transfer are rated as important aspects for innovation and commercialisation of biotechnology-based products and processes. Collaboration with pharmaceutical companies is attractive but whether or not the collaborator will prioritise the biotech's mission is dependent on what was agreed at negotiations (Argyres and Liebeskind, 2002) . The downside is that dedicated biotechnology firms from the outset then become market driven rather than science driven. Universityfunded ventures are also not completely devoid of financial pressures ötherefore, the preference to fund start-ups may or may not be driven by science at the university-based science parks. The new entrepreneurial mission of the state university with its emphasis on profiting from innovation in biosciences is therefore in conflict with its initial mission of fostering science for societal welfare. How the state will strike a balance in being a partner, that is, expecting universities to profit from state-funded R&D, and a regulator (determining what can or cannot be approved in biomanufacturing) is another chapter in the study of the evolving relationship between the state and the industry. This evolving nature of the relationship is exemplified in the current discussion the Biotechnology Industry Association is having with the federal government in improving regulatory processes within the FDA.
Future studies need to examine critically the role of the state in fostering the development of a bioscience-based industry cluster near all major US state universities. In other words, can policy instruments alone facilitate the transformation of any university town into a vibrant biotechnology cluster? In addition, the study of the relationship between new technologies and the development of regulations is another important aspect of research necessary for understanding the interrelationship of policy and practice in the biotechnology industry.
